GW Pharmaceuticals plc announced the appointment of Stephen D. Schultz to the new role of Vice President, Investor Relations. Mr. Schultz will be based in the United States. Mr. Schultz has close to 25 years of experience in investor relations, financial communications and media relations.

Most recently, Mr. Schultz served as Senior Director of Investor Relations and Corporate Communications at Amarin Corporation plc At Amarin, Mr. Schultz led the company's investor program from Phase 3 clinical trials of its lead product Vascepa® through approval from the U.S. Food and Drug Administration in 2012 and U.S. commercial launch in January 2013.